We focus on the acquisition, development and commercialization of innovative pharmaceutical products. Our strategy is to focus on the medical specialist, particularly in the areas of urology and endocrinology. Our distinctive product portfolio includes multiple late stage compounds, including treatments for overactive bladder, male hypogonadism, prostate and bladder cancer, central precocious puberty, and the prevention of infection by HIV and other sexually transmitted pathogens.